



ASX Announcement
23 November 2023

CHANGE OF COMPANY AUDITOR

Optiscan Imaging Limited (ASX: OIL) ('the Company' or 'Optiscan') advises that in accordance with ASX Listing Rule 3.16.3, William Buck Audit (Vic) Pty Ltd (William Buck) has been appointed as auditor of the Company following the resignation of Grant Thornton Audit Pty Ltd (Grant Thornton). The appointment of William Buck was subject to shareholder approval at today's AGM and ASIC consent.

The Company confirms that ASIC has provided their consent and shareholder approval was granted at today's Annual General Meeting for the proposed appointment.

Further details in relation to the change of Company Auditor were included in the Company's Notice of Annual General Meeting dated 24 October 2023.

The Board of Directors would like to thank Grant Thornton for their past assistance and services provided to the Company.

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For investor queries, please contact:

Dr. Camile Farah

Chief Executive Officer & Managing Director – Optiscan Imaging Ltd

E: cfarah@optiscan.com

About Optiscan

Optiscan Imaging Ltd (ASX:OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

P: (61 3) 9538 3333

A: 16 Miles St, Mulgrave VIC 3170, Australia

W: www.optiscan.com